Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure

Nephrology Dialysis Transplantation

Volumn 11, Issue 11, 1996, Pages 2237-2243

  Samuelsson, O ^a,d   Attman, P O ^a   Knight Gibson, C ^b   Larsson, R ^a   Mulec, H ^a   Wedel, H ^c   Weiss, L ^a   Alaupovic, P ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apolipoproteins; Chronic renal disease; Glomerular filtration rate; Lipoprotein (a); Progression

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS; RISK; THROMBOSIS;

EID: 0029853513     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027142     Document Type: Article

References (45)

1. Utermann G. The mysteries of lipoprotein (a). Science 1989; 246: 904-910
2. Miles LA, Fless LA, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989; 339: 301-303
3. Scanu AM. Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267: 3326-3329
4. Rader DJ, Brewer HB Jr. Lipoprotein (a): clinical approach to a unique atherogenic lipoprotein. JAMA 1992; 267: 1109-1112
5. Kronenberg F. Lipoprotein (a) in renal disease: what we have, what we need, what we can forget. Nephrol Dial Transplant 1995; 10: 766-769
6. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Lipoprotein (a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992; 22: 243-248
7. Wanner C, Bartens W. Lipoprotein (a) in renal patients: is it a key factor in the high cardiovascular mortality? Nephrol Dial Transplant 1994; 9: 1066-1068
8. Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C. Comparison of Lp(a) concentrations and some potential effects of hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995; 70: 155-170
9. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein (a) in renal disease. Am J Kidney Dis 1996; 27: 1-25
10. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S-I, Arakawa M. Localization of apolipoprotein (a) and B-100 in various renal diseases. Kidney Int 1993; 43: 430-435
11. Krämer-Guth A, Greiber S, Pavenstädt H, Quaschning T, Winkler K, Schollmeyer P, Wanner C. Interaction of native and oxidized lipoprotein (a) with human mesangial cells and matrix. Kidney Int 1996; 49: 1250-1261
12. Greiber S, Krämer-Guth A, Pavenstädt H, Gutenkunst M, Schollmeyer P, Wanner C. Effects of lipoprotein (a) on mesangial cell proliferation and viability. Nephrol Dial Transplant 1996; 11: 778-785
13. Samuelsson O, Attman P-O, Alfredsson A, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P. Apo-B-containing lipoproteins accelerate progression of renal insufficiency (Abstract). XIIIth International Congress of Nephrology, Madrid, Spain, June 1995
14. Jagenburg R, Attman P-O, Aurell M, Bucht H. Determination of glomerular filtration rate in advanced renal insufficiency. Stand J Urol Nephrol 1978; 12: 133-137
15. Attman P-O, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991; 57: 401-410
16. 3H] cholesterol linoleyl ether-labelled human Lp(a) in different rat organs. Biochim Biophys Acta 1988; 963: 534-540
17. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein (a), apolipoprotein B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318-1328
18. Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H. Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119: 263-269
19. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721
20. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-482
21. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman P-O. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993; 63: 279-285
22. Grützmacher P, März W, Peschke B, Gross W, Schoeppe W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50: 103-111
23. Lacour B, Roullet J-B, Beyne P, Kreis H, Thevenin M, Drüeke T. Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 1985; 23: 805-810
24. Bergesio F, Monzani G, Ciuti R, Serruto A, Benucci A, Frizzi V, Salvadori M. Lipids and apolipoproteins change during progression of chronic renal failure. Clin Nephrol 1992; 38: 264-270
25. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein (a) and apolipoprotein (a) phenotypes in patient with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120
26. Sechi LA, De Carli S, Zingaro L, Feletto F, Di Poi E, Falleti E, Bartoli E. Serum lipoprotein (a) and apolipoprotein levels in patients with mild renal failure (Abstract). ASN 28th Annual Meeting Nov 5-8, 1995. J Am Soc Nephrol 1995; 6: 402
27. Striker G. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. J Am Soc Nephrol 1995; 5: 1537-1540
28. Walser M. Progression of chronic renal failure in man. Kidney Int 1990; 37: 1195-1210
29. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992; 90: 220-230
30. Black IW, Wilcken DE. Decreases in apolipoprotein (a) after renal transplantation: implications for lipoprotein (a) metabolism. Clin Chem 1992; 38: 353-357
31. Gansevoort RT, Heeg JE, Dikkeschei FD, de Zeeuw D, de Jong PE, Dullaart RPF. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244-250
32. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H. Apolipoprotein (a) phenotype associated decrease in lipoprotein (a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994; 14: 1399-1404
33. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle W, Utermann G. Apo (a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 1214-1226
34. Farrer M, Game FL, Albers CJ, Neil AW, Winocour PH, Laker MF, Adams PC, Alberti GMM. Coronary artery disease is associated with increased lipoprotein (a) concentrations independent of the size of circulation apolipoprotein (a) isoforms. Arterioscler Thromb 1994; 14: 1272-1283
35. Haffner SM, Gruber KK, Aldrete G, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein (a) concentrations in chronic renal failure. J Am Soc Nephrol 1992; 3: 1156-1162
36. Simons LA, Lipoprotein (a): important risk factor or passing fashion? Med J Aust 1993; 158: 512-514
37. Goldstein MR. Lipoprotein (a): friend or foe? Am J Cardiol 1995; 75: 319
38. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67
39. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199
40. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H, Kutsumi Y, Yamada N, Noma A, Yamaguchi H. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994; 73: 1037-1040
41. Attman P-O, Samuelsson O, Alaupovic P. Lipid metabolism and renal failure. Am J Kidney Dis 1993; 21: 373-592
42. Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991; 338: 419-423
43. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-1666
44. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, and the MDRD Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884
45. Wight JP, Salzano S, Brown CB, El Nahas AM. Natural history of chronic renal failure: a reappraisal. Nephrol Dial Transplant 1992; 7: 379-383